Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Frontiers in Immunology
|
June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Amy K Erbe, Wei Wang, Patrick K Reville, et al.
Blood Cancer Journal
|
March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood
|
April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes
Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Blood
|
March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
Warren Fiskus, Jessica Piel, Mike Collins, et al.
Biorxiv : the Preprint Server for Biology
|
May 18, 2026
Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and Resistance
Mostafa I H Ali, Zeynep Feyza Akpinar, Jose A Ovando-Ricardez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Naval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Cancer Cell
|
March 8, 2024
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions
Qing Deng, Priya Lakra, Panhong Gou, et al.
American Journal of Hematology
|
September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Cancer Immunology Research
|
June 7, 2023
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Poonam N Desai, Bofei Wang, Andre Fonseca, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Frontiers in Immunology
|
June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Amy K Erbe, Wei Wang, Patrick K Reville, et al.
Blood Cancer Journal
|
March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood
|
April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes
Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Blood
|
March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
Warren Fiskus, Jessica Piel, Mike Collins, et al.
Biorxiv : the Preprint Server for Biology
|
May 18, 2026
Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and Resistance
Mostafa I H Ali, Zeynep Feyza Akpinar, Jose A Ovando-Ricardez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Naval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Cancer Cell
|
March 8, 2024
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions
Qing Deng, Priya Lakra, Panhong Gou, et al.
American Journal of Hematology
|
September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Cancer Immunology Research
|
June 7, 2023
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Poonam N Desai, Bofei Wang, Andre Fonseca, et al.
Page
of 4